Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Protara Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TARA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: TARA's weekly volatility (12%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: TARA underperformed the US Biotechs industry which returned 24.4% over the past year.
Return vs Market: TARA underperformed the US Market which returned 49.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Protara Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWhat Type Of Shareholders Make Up Protara Therapeutics, Inc.'s (NASDAQ:TARA) Share Registry?
3 months ago | Simply Wall StHow Many Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Have Insiders Sold, In The Last Year?
7 months ago | Simply Wall StCould The Protara Therapeutics, Inc. (NASDAQ:TARA) Ownership Structure Tell Us Something Useful?
Is Protara Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TARA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TARA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TARA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: TARA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TARA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TARA is good value based on its PB Ratio (0.6x) compared to the US Biotechs industry average (3.4x).
How is Protara Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TARA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TARA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TARA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if TARA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if TARA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TARA's Return on Equity is forecast to be high in 3 years time
How has Protara Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TARA is currently unprofitable.
Growing Profit Margin: TARA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TARA is unprofitable, and losses have increased over the past 5 years at a rate of 67.2% per year.
Accelerating Growth: Unable to compare TARA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TARA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).
Return on Equity
High ROE: TARA has a negative Return on Equity (-19.87%), as it is currently unprofitable.
How is Protara Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: TARA's short term assets ($87.7M) exceed its short term liabilities ($3.3M).
Long Term Liabilities: TARA's short term assets ($87.7M) exceed its long term liabilities ($974.0K).
Debt to Equity History and Analysis
Debt Level: TARA is debt free.
Reducing Debt: TARA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TARA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TARA has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 69.4% each year.
What is Protara Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TARA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TARA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TARA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TARA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TARA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jesse Shefferman (48 yo)
Mr. Jesse Shefferman is the Co-Founder of Proteon Therapeutics Inc. (Formerly known as Protara Therapeutics, Inc. (formerly known as ArTara Therapeutics, Inc.).) and also serves as its President & CEO sinc...
CEO Compensation Analysis
Compensation vs Market: Jesse's total compensation ($USD7.76M) is above average for companies of similar size in the US market ($USD532.21K).
Compensation vs Earnings: Jesse's compensation has increased whilst the company is unprofitable.
Experienced Management: TARA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: TARA's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 92.2%.
Protara Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Protara Therapeutics, Inc.
- Ticker: TARA
- Exchange: NasdaqGM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$110.377m
- Shares outstanding: 11.23m
- Website: https://www.protaratx.com
Number of Employees
- Protara Therapeutics, Inc.
- 345 Park Avenue South
- 3rd Floor
- New York
- New York
- United States
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead p...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/09 23:37|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.